Solid Biosciences to Participate at the Barclays Gene Editing & Therapy Summit
May 22 2023 - 8:00AM
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company
developing genetic medicines for neuromuscular and cardiac
diseases, today announced that Bo Cumbo, President and Chief
Executive Officer, will participate in a fireside chat at the
Barclays Gene Editing & Therapy Summit on Wednesday, May 24,
2023 at 11:30 AM ET.
A live webcast of the fireside chat will be
available on the Events page of the Investors section of the
Company website or by clicking here. A webcast replay will be
archived for 30 days on the Events page.
Institutional investors interested in meeting
with management during the conference may reach out to their
Barclays representative.
About Solid
Biosciences Solid Biosciences is a life science
company focused on advancing a portfolio of neuromuscular and
cardiac programs, including SGT-003, a differentiated gene transfer
candidate for the treatment of Duchenne, AVB-202-TT, a gene
transfer candidate for the treatment of Friedreich’s Ataxia,
AVB-401 for BAG3 mediated dilated cardiomyopathy, and additional
assets for the treatment of undisclosed cardiac diseases. Solid
aims to be the center of excellence across a given disease spectrum
bringing together those with expertise in science, technology,
disease management, and care. Patient-focused and founded by those
directly impacted, Solid’s mandate is to improve the daily lives of
patients living with these devastating diseases. For more
information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:Leah
MonteiroVP of Investor Relations &
Communications617-821-4427lmonteiro@solidbio.com
Solid Biosciences Media Contact:Tim
PalmerAssociate Director, Corporate Communications
607-760-4223Tim@solidbio.com
Solid Biosciences (NASDAQ:SLDB)
Historical Stock Chart
From Apr 2024 to May 2024
Solid Biosciences (NASDAQ:SLDB)
Historical Stock Chart
From May 2023 to May 2024